What should investors evaluating the neurodegenerative disease market watch beyond approval headlines?

Watch infusion capacity and MRI throughput at treating centers. Approval creates eligibility; site capacity determines actual revenue timing, and most launch models have overestimated it [4]. Read More

How do buyers assess whether an antibody supplier can support a hospital contract?

Ask for ARIA monitoring support, MRI scheduling assistance, and reimbursement navigation staffing. Product differentiation in this class is thin, so service wrap decides most institutional contracts [1][3]. Read More

Which competitive dynamic is most underestimated in the neurodegenerative disease market?

Delivery format, not mechanism. A subcutaneous or monthly option can take share from a clinically equivalent biweekly infusion simply by freeing chair time and caregiver hours [4][5]. Read More

What regulatory nuance most often surprises companies entering Europe?

Marketing authorization and funded access are separate hurdles. National HTA bodies can restrict eligible populations further than the EMA already has, adding 12–24 months before meaningful volume [14]. Read More

How reliable is external-control-arm evidence for rare neurodegenerative indications?

Less reliable than sponsors assumed. Regulatory acceptance can shift mid-program, as one Huntington's gene therapy developer discovered when prior FDA alignment was reversed at the pre-BLA stage [11]. Read More

What integration challenge slows plasma biomarker testing adoption in primary care?

Result interpretation. Positive amyloid status in a cognitively normal patient has no approved treatment pathway, so health systems need referral protocols before deploying screening broadly [6]. Read More

Which emerging use case could expand the neurodegenerative disease market fastest after 2030?

Secondary prevention in asymptomatic biomarker-positive adults. A single positive readout would shift the category from specialist treatment to screened primary care. Read More

Neurodegenerative Disease Market (2025 - 2035)

Neurodegenerative Disease Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Huntington's Disease), By Diagnosis Method (Neurological Examination, Imaging Techniques, Cerebrospinal Fluid Analysis, Electrophysiological Tests), By Treatment Type (Medication, Therapy, Rehabilitation, Surgical Interventions), By Route of Administration (Oral, Injectable, Intravenous, Transdermal) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025-2035

CAGR

7.5%

2025 Market Size

USD 54.93 Billion

2035 Market Size

USD 112.72 Billion

Life Sciences ● Updated August 2026 Report ID: MRFR/LS/17671-HCR | Pages: 200 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Population Aging and Prevalence Load | |
  2. 3.1.2 Disease-Modifying Antibody Uptake | |
  3. 3.1.3 Blood-Based Diagnostic Reclassification | |
  4. 3.1.4 Public Funding and National Dementia Plans | |
  5. 3.1.5 Advanced-Stage Parkinson's Delivery Innovation | |
  6. 3.1.6 Genetically Defined Subtype Targeting | |
  7. 3.1.7 Asia-Pacific Screening Mandates |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Generic Erosion in Symptomatic Classes | |
  2. 3.2.2 Payer Restriction and Divergent HTA Outcomes | |
  3. 3.2.3 Infusion and MRI Infrastructure Limits | |
  4. 3.2.4 Clinical Trial Attrition | |
  5. 3.2.5 Diagnostic Delay in Low-Resource Settings |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Prodromal and Preventive Treatment | |
  2. 3.3.2 Emerging-Market Access Models | |
  3. 3.3.3 Real-World Evidence and Registry Monetization | |
  4. 3.3.4 Genetically Defined Subtypes | |
  5. 3.3.5 Home-Delivered Maintenance |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Neurodegenerative Disease Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Indication | |
  1. 5.1.1 Alzheimer's Disease | |
  2. 5.1.2 Parkinson's Disease | |
  3. 5.1.3 Multiple Sclerosis | |
  4. 5.1.4 Amyotrophic Lateral Sclerosis | |
  5. 5.1.5 Huntington's Disease | |
  6. 5.1.6 Other Indications |
2. 5.2 By Drug Class | |
  1. 5.2.1 Cholinesterase Inhibitors | |
  2. 5.2.2 NMDA Antagonists | |
  3. 5.2.3 Dopaminergic Agents | |
  4. 5.2.4 Immunotherapies and Monoclonal Antibodies | |
  5. 5.2.5 Gene and Cell Therapies | |
  6. 5.2.6 Other Symptomatic Agents |
3. 5.3 By Molecule Type | |
  1. 5.3.1 Small-Molecule Drugs | |
  2. 5.3.2 Biologics and Monoclonal Antibodies | |
  3. 5.3.3 RNA-Based Therapeutics | |
  4. 5.3.4 Cell and Gene Therapies |
4. 5.4 By Route of Administration | |
  1. 5.4.1 Oral | |
  2. 5.4.2 Injectable / Parenteral | |
  3. 5.4.3 Transdermal / Intranasal |
5. 5.5 By Distribution Channel | |
  1. 5.5.1 Hospital Pharmacies | |
  2. 5.5.2 Retail Pharmacies | |
  3. 5.5.3 Online Pharmacies
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of Middle East & Africa
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2026) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Biogen | |
  2. 7.3.2 Eisai | |
  3. 7.3.3 Eli Lilly | |
  4. 7.3.4 AbbVie | |
  5. 7.3.5 Roche / Genentech | |
  6. 7.3.6 Novartis | |
  7. 7.3.7 Teva | |
  8. 7.3.8 Lundbeck | |
  9. 7.3.9 UCB | |
  10. 7.3.10 Supernus Pharmaceuticals | |
  11. 7.3.11 Denali Therapeutics | |
  12. 7.3.12 uniQure
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 Near-Term Outlook (2026–2028) |
2. 8.2 Medium-Term Outlook (2029–2031) |
3. 8.3 Long-Term Outlook (2032–2035)
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Neurodegenerative Disease Market Size & Forecast, by Revenue (USD billion), 2021–2035 |
TABLE 2 Global Neurodegenerative Disease Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Global Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 6 Global Neurodegenerative Disease Market Size, by Drug Class, 2021–2035 (USD billion) |
TABLE 7 Global Neurodegenerative Disease Market Size, by Molecule Type, 2021–2035 (USD billion) |
TABLE 8 Global Neurodegenerative Disease Market Size, by Route of Administration, 2021–2035 (USD billion) |
TABLE 9 Global Neurodegenerative Disease Market Size, by Distribution Channel, 2021–2035 (USD billion) |
TABLE 10 Global Neurodegenerative Disease Market Size, by Region, 2021–2035 (USD billion) |
TABLE 11 North America Neurodegenerative Disease Market Size, by Country, 2021–2035 (USD billion) |
TABLE 12 Europe Neurodegenerative Disease Market Size, by Country, 2021–2035 (USD billion) |
TABLE 13 Asia-Pacific Neurodegenerative Disease Market Size, by Country, 2021–2035 (USD billion) |
TABLE 14 South America Neurodegenerative Disease Market Size, by Country, 2021–2035 (USD billion) |
TABLE 15 Middle East & Africa Neurodegenerative Disease Market Size, by Country, 2021–2035 (USD billion) |
TABLE 16 North America Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 17 North America Neurodegenerative Disease Market Size, by Drug Class, 2021–2035 (USD billion) |
TABLE 18 North America Neurodegenerative Disease Market Size, by Route of Administration, 2021–2035 (USD billion) |
TABLE 19 Europe Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 20 Europe Neurodegenerative Disease Market Size, by Drug Class, 2021–2035 (USD billion) |
TABLE 21 Europe Neurodegenerative Disease Market Size, by Distribution Channel, 2021–2035 (USD billion) |
TABLE 22 Asia-Pacific Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 23 Asia-Pacific Neurodegenerative Disease Market Size, by Molecule Type, 2021–2035 (USD billion) |
TABLE 24 Asia-Pacific Neurodegenerative Disease Market Size, by Distribution Channel, 2021–2035 (USD billion) |
TABLE 25 South America Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 26 South America Neurodegenerative Disease Market Size, by Drug Class, 2021–2035 (USD billion) |
TABLE 27 Middle East & Africa Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 28 Middle East & Africa Neurodegenerative Disease Market Size, by Drug Class, 2021–2035 (USD billion) |
TABLE 29 United States Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 30 United States Neurodegenerative Disease Market Size, by Route of Administration, 2021–2035 (USD billion) |
TABLE 31 Germany Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 32 United Kingdom Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 33 Japan Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 34 China Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 35 India Neurodegenerative Disease Market Size, by Drug Class, 2021–2035 (USD billion) |
TABLE 36 Brazil Neurodegenerative Disease Market Size, by Drug Class, 2021–2035 (USD billion) |
TABLE 37 Saudi Arabia Neurodegenerative Disease Market Size, by Indication, 2021–2035 (USD billion) |
TABLE 38 Competitive Benchmarking Matrix – Global Neurodegenerative Disease Market, 2026 |
TABLE 39 Company Profiles – Key Players, Global Neurodegenerative Disease Market |
TABLE 40 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 41 Report Scope & Methodology Summary |
TABLE 42 Detailed Sources and Citations Index
13 LIST OF FIGURES |
FIGURE 1 Global Neurodegenerative Disease Market Dynamics – Drivers, Restraints, Opportunities |
FIGURE 2 Industry Value Chain Analysis – Discovery to Patient Administration |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend and Forecast, 2021–2035 (USD billion) |
FIGURE 5 Year-over-Year Growth Rate Trend, 2022–2035 (%) |
FIGURE 6 Market Share by Indication, 2025 vs 2035 (%) |
FIGURE 7 Market Share by Drug Class, 2025 (%) |
FIGURE 8 Market Share by Molecule Type, 2025 (%) |
FIGURE 9 Market Share by Route of Administration, 2025 (%) |
FIGURE 10 Market Share by Distribution Channel, 2025 (%) |
FIGURE 11 Regional Market Share, 2025 (%) |
FIGURE 12 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 13 North America Country-Level Share, 2025 (%) |
FIGURE 14 Europe Country-Level Share, 2025 (%) |
FIGURE 15 Asia-Pacific Country-Level Share, 2025 (%) |
FIGURE 16 Competitive Landscape – Estimated Revenue Share Bands, 2026 |
FIGURE 17 Competitive Positioning Matrix – Pipeline Depth vs Commercial Reach |
FIGURE 18 Regulatory Milestone Timeline, 2021–2026

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Indication	Alzheimer's Disease; Parkinson's Disease; Multiple Sclerosis; Amyotrophic Lateral Sclerosis; Huntington's Disease; Other Indications	Alzheimer's Disease	Amyotrophic Lateral Sclerosis
By Drug Class	Cholinesterase Inhibitors; NMDA Antagonists; Dopaminergic Agents; Immunotherapies and Monoclonal Antibodies; Gene and Cell Therapies; Other Symptomatic Agents	Cholinesterase Inhibitors	Gene and Cell Therapies
By Molecule Type	Small-Molecule Drugs; Biologics and Monoclonal Antibodies; RNA-Based Therapeutics; Cell and Gene Therapies	Small-Molecule Drugs	RNA-Based Therapeutics
By Route of Administration	Oral; Injectable / Parenteral; Transdermal / Intranasal	Oral	Transdermal / Intranasal
By Distribution Channel	Hospital Pharmacies; Retail Pharmacies; Online Pharmacies	Hospital Pharmacies	Online Pharmacies
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Indication

Sub-Segment	Key Trend
Alzheimer's Disease	Amyloid-directed antibodies establish a premium price tier above a generic symptomatic base.
Parkinson's Disease	Continuous infusion and wearable pumps convert generic molecules into device-drug premiums.
Multiple Sclerosis	Mature high-efficacy therapy market facing biosimilar entry on legacy agents.
Amyotrophic Lateral Sclerosis	Antisense success in SOD1 subtype drives genetically stratified development.
Huntington's Disease	Gene therapy filings face evolving evidentiary standards for external control arms.
Other Indications	Rare ataxias and atypical parkinsonism attract orphan-designation development.

Indication mix determines pricing power more than volume. Alzheimer's supplies the largest patient pool but the most contested value proposition, while smaller genetically defined indications command premium pricing on far lower unit volumes.

By Drug Class

Sub-Segment	Key Trend
Cholinesterase Inhibitors	Volume-stable, value-eroding generic backbone of dementia care
NMDA Antagonists	Steady use in moderate-to-severe dementia with limited pricing upside
Dopaminergic Agents	Reformulation and delivery innovation extend commercial life of levodopa.
Immunotherapies and Monoclonal Antibodies	Fastest revenue accretion in absolute dollars through 2030
Gene and Cell Therapies	Highest growth rate from a small base; regulatory pathway still forming
Other Symptomatic Agents	Agitation and sleep comorbidity products fill unmet supportive-care gaps.

Class economics diverge sharply. Two classes supply most volume, two supply most growth, and almost none supply both.

By Molecule Type

Sub-Segment	Key Trend
Small-Molecule Drugs	Oral convenience sustains share despite minimal pricing power
Biologics and Monoclonal Antibodies	Delivery format increasingly differentiates otherwise similar agents.
RNA-Based Therapeutics	Intrathecal antisense expands into additional monogenic targets.
Cell and Gene Therapies	One-time dosing challenges conventional annual-cost reimbursement models

Molecule type increasingly predicts the payer conversation. Small molecules negotiate on price; biologics and gene therapies negotiate on outcome guarantees.

By Route of Administration

Sub-Segment	Key Trend
Oral	Default for symptomatic maintenance across all severity stages
Injectable / Parenteral	Required for antibody induction and intrathecal antisense dosing
Transdermal / Intranasal	Fastest growth as swallowing difficulty rises in advanced disease.

Route decisions now carry commercial weight equal to efficacy data, because they determine site of care and therefore who holds the budget.

By Distribution Channel

Sub-Segment	Key Trend
Hospital Pharmacies	Anchored by infusion administration and imaging surveillance requirements
Retail Pharmacies	Chronic oral refill volume with thin margins
Online Pharmacies	Caregiver-driven home delivery expands fastest across all channels.

Channel share will shift as subcutaneous maintenance formats scale, moving value from hospital pharmacy toward specialty distribution and direct-to-home fulfilment.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”